Skip to content
Clinical Trials – home
FranceBack to France

Clinical trials in Quint-Fonsegrives – page 58

1 508 clinical trials in Quint-Fonsegrives, France across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Quint-Fonsegrives at a glance
1 508
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 508 trials in Quint-Fonsegrives

Open in trial search

Neoplasm

Not yet recruiting

Study of IDE849, IDE‑161 and durvalumab evaluating safety and efficacy in patients with DLL3‑positive tumors including small cell lung cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Ideaya Biosciences Inc.

Prostate cancer

Not yet recruiting

Evaluation of piflufolastat (18F) PET/CT for monitoring prostate cancer recurrence in patients with favourable intermediate‑risk localized disease after focal HIFU

Registered drugNo placebo
Countries:FranceFrance
  • Participants:65+ years
  • Sponsor:Centre Hospitalier Universitaire De Toulouse

Evaluation of Propranolol‑Enhanced Traumatic Memory Reactivation for Post‑Traumatic Stress Disorder in Women Victims of Violence

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Propranolol Hydrochloride
  • Sponsor:Centre Hospitalier Universitaire De Toulouse

Systemic scleroderma+1

Not yet recruiting

Study of CC-97540 (CD19‑Targeted NEX‑T CAR T) versus drug combination in adults with active systemic sclerosis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:CC-97540
  • Sponsor:Celgene Corp.

Colitis ulcerative

Not yet recruiting

Safety and efficacy of stopping versus maintenance dose of filgotinib, tofacitinib and upadacitinib in adult ulcerative colitis patients in deep remission

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Filgotinib
  • Sponsor:Assistance Publique Hopitaux De Marseille

Interstitial lung disease+2

Not yet recruiting

Long‑term Safety and Tolerability of Admilparant in Adults with Idiopathic or Progressive Pulmonary Fibrosis

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Admilparant
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Cardiac failure

Not yet recruiting

Effect of Acetazolamide Added to Standard Therapy on Weight Reduction and Symptom Relief in Patients with Heart Failure

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Acetazolamide
  • Sponsor:Centre Hospitalier Universitaire De Montpellier

Randomized phase III adjuvant capecitabine plus temozolomide versus surveillance in patients with resected stage I‑III pancreatic neuroendocrine tumors

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Institut Gustave Roussy

Rituximab versus clinic‑biological monitoring for ANCA reactivation in patients with GPA or MPA (with prednisolone)

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Prednisolone
  • Sponsor:Assistance Publique Hopitaux De Paris

Postoperative oxaliplatin liver‑directed chemotherapy plus drug combination in patients with resected colorectal liver metastases at high risk of recurrence

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Levofolinate
  • Sponsor:Unicancer

Subarachnoid haemorrhage

Not yet recruiting

Ticagrelor versus placebo to prevent cerebral ischemia in patients with low‑grade aneurysmal subarachnoid hemorrhage

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ticagrelor
  • Sponsor:Centre Hospitalier Universitaire De Toulouse

T-cell type acute leukaemia

Not yet recruiting

Evaluating venetoclax with drug combination in relapsed/refractory T‑cell acute lymphoblastic leukemia patients

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Asparaginase
  • Sponsor:Centre Hospitalier De Versailles

Other cities in France

The busiest research cities in the country

All 366 cities in France

Clinical research in Quint-Fonsegrives

What the registry says about research in the country

01 Urological Research

Extensive research focusing on bladder cancer treatments, including innovative therapies for both muscle-invasive and non-muscle-invasive cases. Studies also address prostate conditions, from benign hyperplasia to advanced cancer.

  • Advanced bladder cancer treatments
  • Prostate cancer therapy optimization
  • Kidney stone management

Novel approaches combine immunotherapy with targeted treatments to improve patient outcomes.

02 Oncology Studies

Comprehensive research into breast cancer treatments, particularly focusing on triple-negative and hormone receptor-positive variants. Studies evaluate new approaches in colon cancer management using circulating tumor DNA analysis.

  • Triple-negative breast cancer therapy
  • Colorectal cancer treatment
  • Lung cancer interventions

Investigations combine immunotherapy with traditional treatments for enhanced efficacy.

03 Specialized Medicine

Research addressing pulmonary conditions and specialized medical needs. Studies include evaluation of treatments for chronic obstructive pulmonary disease and migraine management in emergency settings.

  • COPD treatment optimization
  • Migraine therapy
  • Diabetic eye conditions

Focus on improving patient quality of life through innovative therapeutic approaches.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.